How much does Direct Meds charge for oral semaglutide?

Direct Meds lists $249 per month for oral semaglutide at its month to month, sublingual term. Counting everything the company states is required, the first month comes to $249. Read from directmeds.com on September 3, 2026.

How much does Direct Meds charge for compounded semaglutide?

Direct Meds lists $297 per month for compounded semaglutide at its month to month, injection term. Counting everything the company states is required, the first month comes to $297. Read from directmeds.com on September 3, 2026.

Company

Direct Meds

Direct Meds publishes oral semaglutide, compounded semaglutide and compounded tirzepatide, from $249 to $297 a month.

3 programs
3 molecules
9 readings

Read from directmeds.com on September 3, 2026. This page records what the company publishes. It is not a review and takes no position on the company.

Go to Direct Meds

Enroll with Direct Meds

This is a paid link. If you enroll through it, Treatment Registry may earn a commission. It does not change what we record, and it does not change the price you pay.

What it costs

Oral semaglutideOral tablet$249

first month, everything required included · Month to month, sublingual

Compounded semaglutideSublingual$297

first month, everything required included · Month to month, injection

Terms

Pharmacy	Not disclosed
Membership	None. “What you see is what you pay-no membership fees, no surprise charges, and no pressure.”
Consultation fee	Not disclosed

Not yet checked: states.

Those the company does not disclose were checked on August 31, 2026.

Terms can differ between this company’s programs; each entry carries its own.

Programs

Entry	Provider	Form	Per month at its shortest term	Link
TR-0019	Direct Meds	Oral tablet	$249 Month to month, sublingual	EnrollPaid link
TR-0020	Direct Meds	Sublingual	$297 Month to month, injection	EnrollPaid link
TR-0021	Direct Meds	Sublingual	Not recorded	EnrollPaid link

Notes

Recorded against this company rather than one program.

August 31, 2026

1. Direct Meds carries an FDA warning letter, number 716822, issued September 2025 and published in FDA's warning-letter index, concerning the online sale and labeling of compounded semaglutide and tirzepatide. No FDA action has halted the business and it continues to operate. Most warning letters concern marketing and labeling claims rather than a finding that a company cannot trade, and we record them rather than treating them as a verdict.

Before you act

Compare Direct Meds with

Cite this

Treatment Registry. (2026). Direct Meds: recorded programs and prices. Last verified September 3, 2026. Retrieved [your access date], from https://treatmentregistry.com/providers/direct-meds